2 Healthcare Stocks to Buy and 1 to Approach With Caution [Yahoo! Finance]
BioNTech (BNTX) had its "buy" rating reaffirmed by Berenberg Bank.
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
BioNTech (BNTX) had its price target raised by Morgan Stanley from $125.00 to $126.00. They now have an "overweight" rating on the stock.
BioNTech (BNTX) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.